share_log

424B3: Prospectus

424B3: Prospectus

424B3:募資說明書
美股SEC公告 ·  08/20 05:03

牛牛AI助理已提取核心訊息

Conduit Pharmaceuticals Inc. has filed a Form 8-K with the SEC, disclosing non-compliance with Nasdaq's continued listing requirements. Specifically, the company's market value of publicly held shares and market value of listed securities fell below the minimum thresholds. Conduit has 180 days to regain compliance. Additionally, undisclosed dispositions of substantial company shares by a director and a significant stockholder's shares being under third-party pledge were discovered. The board has formed a Special Committee and a Trading Review Committee to investigate and address these issues.
Conduit Pharmaceuticals Inc. has filed a Form 8-K with the SEC, disclosing non-compliance with Nasdaq's continued listing requirements. Specifically, the company's market value of publicly held shares and market value of listed securities fell below the minimum thresholds. Conduit has 180 days to regain compliance. Additionally, undisclosed dispositions of substantial company shares by a director and a significant stockholder's shares being under third-party pledge were discovered. The board has formed a Special Committee and a Trading Review Committee to investigate and address these issues.
Conduit Pharmaceuticals公司向SEC提交了8-k表格,披露未遵守納斯達克的繼續上市要求。具體來說,該公司公開持有股票市值和上市證券市值均低於最低門檻。Conduit有180天時間恢復遵守規定。此外,董事未公開出售大量公司股份,以及重要股東的股份被第三方抵押。董事會已成立特別委員會和交易審核委員會,調查和解決這些問題。
Conduit Pharmaceuticals公司向SEC提交了8-k表格,披露未遵守納斯達克的繼續上市要求。具體來說,該公司公開持有股票市值和上市證券市值均低於最低門檻。Conduit有180天時間恢復遵守規定。此外,董事未公開出售大量公司股份,以及重要股東的股份被第三方抵押。董事會已成立特別委員會和交易審核委員會,調查和解決這些問題。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。